Constant-routine protocol reveals an endogenous circadian rhythm in diet-induced thermogenesis with a peak in the biological morning.

MetabolismMay 25, 2026 (epub)
Clinical ResearchEndocrinologyGastroenterologyOpen access

Nina Vujović, Han-Chow E Koh, Su Wei Heng et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the influence of the endogenous circadian system on diet-induced thermogenesis (DIT) in 16 healthy adults with overweight or obesity. The study found a significant circadian rhythm in DIT, peaking in the biological morning with a peak-to-trough amplitude of 44% (∼10 kcal/4 h), suggesting that meal timing may impact body mass through thermogenic responses.

Key findings

  • The peak-to-trough amplitude of DIT was 44% (∼10 kcal/4 h), peaking in the biological morning.
  • Circadian rhythm in DIT remained significant after adjusting for fasting energy expenditure, with a reduced amplitude of ∼29% (∼7 kcal/4 h).
  • The endogenous circadian rhythm in DIT was unaffected by prior early versus late eating schedules.

Why it matters

Understanding the circadian influences on diet-induced thermogenesis can help elucidate mechanisms linking meal timing to body weight regulation, potentially guiding dietary recommendations for weight management.

Source

PubMed · PMID 42190872Free full text on PubMed Central

Published in Metabolism. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.